Executive Summary
The global oncology licensing landscape from 2020 to July 2026 has undergone a structural transformation: deal volumes expanded dramatically, payment structures shifted decisively toward milestone-heavy frameworks, and China emerged as an indispensable source of differentiated oncology assets. For medical professionals engaged in translational research and clinical development, these business patterns are not merely financial abstractions—they directly forecast which therapeutic modalities, target classes, and combination strategies will define standard-of-care settings in the coming decade.
1. Deal Volume and Structure: A Market in Rapid Expansion
Aggregate licensing activity in biopharma accelerated sharply across the review period, with oncology representing a substantial and growing share. Full-year 2025 saw $250.2 billion in total deal value across 516 licensing deals (all biopharma), up from $190.6 billion in 2024, making it the most active year on record 5. In the first half of 2025 alone, oncology licensing totaled 78 deals worth $46.9 billion 5. Through Q3 2025, global biopharma licensing reached approximately $181.5 billion in announced deal value 17. In H1 2026, biopharma licensing led dealmaking with $166.7 billion in announced R&D value 6.
Critically, the composition of payment structures has evolved. Upfront payments now average approximately 7% of total deal value across broader biotech licensing, with milestones comprising roughly 65% of total value 13. In oncology specifically, upfronts represent a somewhat higher share—approximately 12–18%—reflecting greater clinical validation at signing and competitive intensity for proven assets 12. Royalty rates have remained relatively stable at mid-single to low-double digits for late-stage assets, while equity components and co-development cost-sharing arrangements have become more prevalent 19.
Table 1. Representative High-Value Oncology Licensing Transactions, 2021–2025
| Deal (Licensor → Licensee, Year) | Asset / Modality | Indication | Upfront ($M) | Milestones ($M) | Total Value ($B) |
|---|---|---|---|---|---|
| BioNTech → BMS (2025) | BNT327, bispecific antibody | Extensive-stage NSCLC, SCLC | 1,500 + $2B noncontingent | 7,600 | 11.1 |
| Innovent → Takeda (2025) | IBI363 + ADC assets, Co-Co | Oncology / autoimmune | Not disclosed | Up to 11.4B | 11.4 |
| 3SBio → Pfizer (2025) | SSGJ-707, bispecific antibody | NSCLC, CRC, gynecological | 1,250 | 4,800 | 6.05 |
| Monte Rosa → Novartis (2025) | Degrader platform | Immune-mediated | 120 | ~5,580 | 5.7 |
| Evopoint → Astellas (2025) | XNW27011, CLDN18.2 ADC | Gastric, GEJ, pancreatic | 130 + $70M near-term | 1,340 | 1.54 |
| RemeGen → Seagen* (2021) | Disitamab vedotin (HER2 ADC) | HER2+ cancers | Not fully disclosed | Up to 2.6B | 2.6 |
| Ratio Therapeutics → Novartis (2024) | SSTR2-targeting radiotherapeutic | Cancer (SSTR2+) | Not disclosed | Up to 745M total | 0.745 |
*Seagen was acquired by Pfizer in 2023. Note: Deal terms as publicly disclosed. Milestones and total values represent maximum potential, contingent on clinical and regulatory outcomes.
2. Therapeutic Modality and Target Focus
Three modalities dominated oncology licensing in this period: antibody-drug conjugates (ADCs), bispecific antibodies, and radiopharmaceuticals. Cell therapies and RNA-based approaches represent growing but less mature areas of activity.
Antibody-Drug Conjugates (ADCs) led by deal value and frequency. The global ADC market, valued at $10.8 billion in 2023, is projected to reach $47 billion by 2029 7. Clinical validation anchored by landmark phase III trials—notably the ASCENT trial for sacituzumab govitecan (SG; objective response rate 35% vs. 5%; OS 12.1 vs. 6.7 months in mTNBC) and the DESTINY-Breast01 trial for trastuzumab deruxtecan (T-DXd; ORR 60.9%; median PFS 16.4 months in the initial publication; updated analysis reported ORR 61.4% and mPFS 19.4 months)—established topoisomerase I inhibitor–payload ADCs as transformative agents 24. T-DXd's subsequent expansion into the HER2-low population (IHC 1+ or 2+/ISH−), validated by the DESTINY-Breast04 trial, broadened the addressable market significantly, driving licensing interest in companion diagnostics and combination strategies. Key ADC targets include TROP2, HER2, CLDN18.2, B7-H3, DLL3, and MSLN 721.
Bispecific Antibodies became the dominant modality by deal value in 2025. The BMS–BioNTech ($11.1 billion) and Pfizer–3SBio ($6.15 billion) transactions exemplify the premium assigned to assets with multi-indication potential and clinical validation in first-line NSCLC settings 3. Notably, the first Phase III progression-free survival benefit for a PD-1×VEGF bispecific over standard anti-PD-1 (ivonescimab vs. pembrolizumab in the HARMONi-2 trial) represents a credible competitive challenge to pembrolizumab in first-line NSCLC. Separately, updated overall survival data from the HARMONi trial (ivonescimab plus chemotherapy in EGFR-mutant NSCLC) showed a hazard ratio of 0.76 as of June 2026, further supporting the modality's clinical potential 21. Preclinical and early clinical validation of B7-H3×CD3 bispecific T-cell engagers—demonstrating 20–60% specific lysis in solid tumor models and synergy with MEK inhibitors—is positioning B7-H3 as a next-generation target in NSCLC and bladder cancer 252627.
Radiopharmaceuticals attracted landmark deals, exemplified by Novartis's $745 million partnership with Ratio Therapeutics for an SSTR2-targeting candidate 2. The FDA approval of ¹⁷⁷Lu-PSMA-617 (lutetium vipivotide tetraxetan) in 2023 for mCRPC following the VISION trial validated PSMA-targeted radiotherapy as standard-of-care, stimulating licensing interest in next-generation PSMA ligands and combination approaches 24.
Table 2. Modality and Target Trends in Oncology Licensing, 2020–2026
| Modality | Key Targets | Clinical Validation Status | Licensing Intensity |
|---|---|---|---|
| ADCs | TROP2, HER2, CLDN18.2, B7-H3, DLL3 | Phase III approvals (SG, T-DXd); Phase I/II ongoing | Highest—>56% of China deal value in 2024 |
| Bispecific Antibodies | PD-1×VEGF, CD3 engagers, B7-H3×CD3 | Phase III data emerging (PD-1×VEGF); Phase I/II for solid-tumor engagers | Highest by 2025 deal count |
| Radiopharmaceuticals | PSMA, SSTR2 | Phase III approval (PSMA-617); early-stage (SSTR2) | Rapidly growing |
| Cell Therapies (CAR-T) | CD19, BCMA, dual-target | Approved in hematologic malignancies; solid tumor Phase I | Significant; 48% of global CAR-T candidates from China |
| RNA-based / Small Nucleic Acids | Multiple oncology targets | Early-stage / platform-level | Emerging |
| Targeted Small Molecules (KRAS, EGFR) | KRAS G12C, EGFR exon 20 | Phase II/III data; sotorasib, adagrasib approved | Moderate; competition narrowing valuations |
3. Valuation Drivers: Why Certain Assets Command Premium Pricing
Several consistently identified factors associate with higher oncology licensing valuations 59:
-
Clinical Stage and Proof-of-Concept Strength: Late-stage assets command substantially higher upfronts. Average upfront payments for Phase II assets increased over 460% from 2022 to 2024. However, early-stage platform deals (40% of ADC licensing at preclinical stage) also attract premium valuations when platform technology is validated and manufacturing is scalable 10.
-
Biomarker-Defined Populations: Assets with clear companion diagnostic strategies—such as T-DXd's HER2-low expansion or CLDN18.2-expressing gastric/pancreatic cancer targeting—command higher valuations by defining addressable patient populations and supporting regulatory pathway clarity 2224.
-
Differentiated Safety-Efficacy Profile: T-DXd's ILD signal (grade 5: 2.2% in DESTINY-Breast01) and SG's neutropenia burden (grade 3/4: 46%) illustrate that safety monitoring infrastructure and pharmacovigilance capability are now explicit partner-selection criteria 24.
-
Manufacturing Scalability: Complex biologics—bispecific ADCs, radiopharmaceuticals—command premiums when licensing partners demonstrate manufacturing capability and supply chain resilience 5.
-
Commercial White Space and First-in-Class Potential: Assets addressing underserved indications or offering first-in-class mechanisms achieve substantially higher valuations than "me-too" programs 5.
-
Regulatory Acceleration Pathways: Breakthrough Therapy Designation, Fast Track status, and accelerated approval frameworks significantly enhance deal valuations and accelerate milestone timelines 45.
4. Strategic Signals: China, Patent Cliffs, and Risk-Sharing Models
China's Emergence as a Primary Innovation Source is the defining strategic narrative of this period. China-origin outbound deal value grew from approximately $51.9 billion in 2024 to $135.7 billion in 2025 (+161.5%), with transaction count rising from 94 to 157 deals (+67.0%) 68. Average upfront payments for China-originated assets increased 230%—from $52 million in 2022 to $172 million in 2026 9. As of Q3 2025, approximately 38% of major global biopharma deals originated from Chinese companies 17. Chinese biotech now accounts for 48% of all clinical-phase bispecific projects, 51% of global ADC clinical trials, and 48% of CAR-T candidates globally 9.
Co-development and co-commercialization (Co-Co) models emerged as a defining innovation in deal structure. The largest single China-outbound transaction—Innovent Biologics' $11.4 billion partnership (October 2025)—featured IBI363 (PD-1×IL-2α-bias bispecific antibody) and two ADC assets, with shared development costs at a 40/60 ratio and co-commercialization in the US market 8. This model signals Chinese developers' ambitions to build genuine international development capabilities rather than simply monetizing assets.
Patent Cliff Urgency is a primary structural driver. By 2032, losses of exclusivity affecting at least $173.9 billion in annual brand revenues—including pembrolizumab, apixaban, and semaglutide—are compelling large pharma to license externally 11. Approximately 50% of blockbuster approvals from 2014–2023 were acquired rather than developed internally; Eli Lilly (8 of 13 blockbusters acquired) and AstraZeneca (5 of 13) exemplify this strategy 11. GSK's stated preference—"We would do licensing every day of the week versus M&A if we could, because you can manage risk and reward the partner as value is unlocked"—articulates the industry-wide preference for milestone-based risk-sharing 11.
Regulatory and Geopolitical Reshaping of Deal Architecture: The BIOSECURE Act (enacted December 2025) fundamentally altered deal diligence requirements. Strategic partnerships in 2026 now incorporate provisions for supply chain sovereignty, "step-in" rights tied to regulatory designation, data provenance verification, and operational separability—all particularly relevant for China-origin assets licensed to Western pharma 17.
5. Implications for Medical Professionals
Treatment Paradigm Shifts: The concentration of licensing in bispecific antibodies, ADCs, and cell therapies signals that future oncology treatment will increasingly feature multi-targeted approaches and engineered cellular therapies. PD-1×VEGF bispecifics challenging pembrolizumab in first-line NSCLC represent the most immediate paradigm shift 21. ADC anchoring in HER2+ breast cancer continues with Enhertu, while next-generation ADCs target novel epitopes (DLL3, MSLN, c-MET, CDH17) 21.
Biomarker Testing Infrastructure: Testing rates for established biomarkers approach 95% in NSCLC, 80% in breast and ovarian cancers, and ~75% in prostate cancer 22. As biomarker-defined populations become central to licensing valuations, oncologists should anticipate expanded companion diagnostic requirements across indications including CLDN18.2 in gastric/pancreatic cancer and TROP2 in TNBC and urothelial cancer.
Safety Monitoring Complexity: ILD risk with T-DXd (2.2% fatal in early trials), severe neutropenia with SG (46% grade 3/4), and cytokine-release concerns with T-cell engagers necessitate specialized monitoring protocols. As complex biologics advance through licensing-driven pipelines, clinical teams must prepare for institution-specific pharmacovigilance infrastructure 24.
Combination Strategy and Sequencing: ASCO 2026 data confirm that oncology competition has shifted from whether new therapies work to how to sequence them and who gets access 21. Licensing partnerships increasingly feature multi-asset combination strategies, with milestone payments tied to validation of combination hypotheses (e.g., bispecific + checkpoint inhibitor, ADC + targeted therapy). GLP-1 receptor agonists are emerging as a potential "metabolic oncology" asset class, opening new combination frameworks across tumor types 21.
Evidence Maturity: The prevalence of early-stage licensing (68% of China license-out transactions at preclinical through Phase I) and milestone-heavy deal structures reflects recognition that clinical validation remains incomplete at signing 18. Oncologists should interpret accelerated approvals and post-marketing commitments within this context—future protocol amendments and label refinements are expected as milestone-driven programs mature.
Summary
Global oncology licensing from 2020 to July 2026 reflects a market defined by explosive deal value growth, structural migration toward milestone-based risk-sharing, and the historic emergence of China as a co-equal source of global innovation. Bispecific antibodies, ADCs, and radiopharmaceuticals dominate current licensing activity; HER2, TROP2, CLDN18.2, B7-H3, PSMA, and PD-1×VEGF represent the most strategically active target classes. Valuation premiums are consistently associated with clinical stage, biomarker clarity, manufacturing capability, and regulatory acceleration pathways. For medical professionals, these trends collectively signal an oncology future defined by combination sequencing, precision biomarker-driven patient selection, and the integration of novel modalities—with significant implications for clinical trial design, safety monitoring, companion diagnostic infrastructure, and the evolving standard of care.